# Summary of evidence and Expert Committee recommendations

Cisplatin was originally added to the EML in 1984. In 2009, cisplatin was replaced by carboplatin with a square box for treatment of advanced ovarian cancer. In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, cisplatin was added to the complementary list of the EML for use as a radio-sensitizer in treatment protocols for head and neck cancer. The relevant extract from TRS994 regarding the Expert Committee’s consideration of treatment protocols for early and advanced stage head and neck cancers is attached.